Ardelyx announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,539,299 on February 3 2026 for the oral formulations of tenapanor, the active ingredient in IBSRELA and XPHOZAH. The patent, titled “Oral Formulations of Tenapanor,” expires on November 26 2042, giving the company a 17‑year extension of commercial exclusivity for both products.
The extension is strategically significant because it pushes the effective exclusivity of IBSRELA and XPHOZAH back to the end of 2042. Prior to the grant, the patents covering the formulations were set to expire in August 2033 for IBSRELA and April 2034 for XPHOZAH, meaning the new patent adds roughly nine years of protection for IBSRELA and eight years for XPHOZAH. This extended period reduces the likelihood of generic entry and preserves the company’s pricing power in both the gastrointestinal and renal markets.
Financially, the extended exclusivity supports Ardelyx’s revenue guidance. Management projects IBSRELA revenue of $410–$430 million in 2026 and $1 billion by 2029, while XPHOZAH is expected to generate $110–$120 million in 2026. By securing a longer patent life, Ardelyx can maintain these revenue targets without the pressure of generic competition, thereby reinforcing its long‑term profitability outlook.
The competitive landscape for tenapanor remains focused on the first‑in‑class NHE3 inhibitor niche. While other companies are developing alternative phosphate‑binding agents for dialysis patients, the patent shield limits the ability of competitors to launch lower‑priced generic versions of IBSRELA and XPHOZAH. This advantage is expected to help Ardelyx retain market share in both indications as the company continues to expand its international commercialization partnerships.
CEO Mike Raab said the patent grant “is an important step in extending protections for our portfolio of first‑in‑class medicines in therapeutic areas where there continues to be significant unmet patient need.” He added that the company remains committed to executing a comprehensive intellectual‑property strategy to drive meaningful impacts for patients and create lasting value for shareholders.
Investors have responded positively to the patent extension, citing the reduced uncertainty around future revenue streams and the company’s strengthened competitive position. The announcement, combined with the dismissal of a securities class action lawsuit, has reinforced confidence in Ardelyx’s long‑term prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.